Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure

This study has been completed.
Information provided by:
Armed Forces Capital Hospital, Republic of Korea Identifier:
First received: September 21, 2009
Last updated: April 7, 2010
Last verified: April 2010
The aim is to evaluate the time of positive conversion after exposure to smear positive pulmonary tuberculosis (TB) in a platoon of Korean military, a closed communal setting.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure

Resource links provided by NLM:

Further study details as provided by Armed Forces Capital Hospital, Republic of Korea:

Enrollment: 32
Study Start Date: May 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
A platoon with TB outbreak

Detailed Description:
In a platoon where TB outbreak occurred, we performed low dose chest CT (LDCT), QuantiFERON-TB gold in tube (QFT) and two-step (0, 4weeks) TST for outbreak investigation. We perform QFT at 0, 2, 4, 8 and 12 weeks after initial investigation for soldiers with negative QFT results, and soldiers with positive QFT and normal LDCT took isoniazid and rifampin for 3 months as treatment of latent TB.

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
A military unit in South Korean Army

Inclusion Criteria:

  • All soldiers who assigned to the military platoon where a tuberculosis outbreak occurred

Exclusion Criteria:

  • Soldiers who could not complete study or refused the study protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00981071

Sponsors and Collaborators
Armed Forces Capital Hospital, Republic of Korea
Principal Investigator: Jae-Joon Yim, MD Seoul National University Hospital
  More Information

Responsible Party: Sei Won Lee/Division chief of pulmonology, Armed Forces Capital Hospital Identifier: NCT00981071     History of Changes
Other Study ID Numbers: QFTconversion 
Study First Received: September 21, 2009
Last Updated: April 7, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by Armed Forces Capital Hospital, Republic of Korea:

Additional relevant MeSH terms:
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents processed this record on October 21, 2016